百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ONC 百济神州

交易中 08-27 09:36:41 EDT

373.52

-2.28

-0.61%

最高373.52	最低372.06	成交量4,561
今开372.35	昨收375.80	日振幅0.39%
总市值425.81亿	流通市值320.08亿	总股本1.14亿
成交额169.91万	换手率0.01%	流通股本8,569万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":373.52,"timestamp":1787837783865,"preClose":375.8,"halted":0,"volume":4561,"delay":0,"changeRate":-0.006067056945183687,"floatShares":85693500,"shares":113999999,"eps":5.589356,"marketStatus":"交易中","change":-2.28,"latestTime":"08-27 09:36:41 EDT","open":372.35,"high":373.52,"low":372.06,"amount":1699138.8396700001,"amplitude":0.003885,"askPrice":374.98,"askSize":5,"bidPrice":372.06,"bidSize":45,"shortable":3,"etf":0,"ttmEps":5.589356,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787860800000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":375.8,"preHourTrading":{"tag":"盘前","latestPrice":374.74,"preClose":375.8,"latestTime":"04:06 EDT","volume":457,"amount":170832.15712,"timestamp":1787817974605,"change":-1.06,"changeRate":-0.002821,"amplitude":0.008941},"postHourTrading":{"tag":"盘后","latestPrice":375.8,"preClose":375.8,"latestTime":"19:30 EDT","volume":1565,"amount":588115.8,"timestamp":1787787002491,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.883557,"impliedVol":0.3254,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/ONC","defaultTab":"news","newsList":[{"id":"2662790711","title":"百济神州上半年净利润同比增长386%，百悦泽驱动收入突破32亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662790711","media":"华尔街见闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662790711?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:21","pubTimestamp":1787739684,"startTime":"0","endTime":"0","summary":"百济神州2026年上半年收入同比增长32.3%至32.19亿美元，净利润同比增长385.8%至4.64亿美元，旗舰产品百悦泽上半年全球销售额达23.42亿美元，同比增长34.5%，占公司产品净收入的74%。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3780347","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"百济神州上半年净利润同比增长386%，百悦泽驱动收入突破32亿美元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","ONC","06160"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2662797911","title":"百济神州(06160)发布中期业绩 净利润4.64亿美元 同比增长385.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797911","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662797911?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:10","pubTimestamp":1787739013,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布截至2026年6月30日止6个月中期业绩，收入32.19亿美元，同比增长32.3%;净利润4.64亿美元，同比增长385.8%;每股基本收益0.32美元。截至2026年6月30日的6个月，总收入增幅为32.3%，这主要是由于公司自主研发的产品百悦泽和百泽安销售额增加，以及安进授权产品销售额增加所致。2026年上半年，我们的GAAP净利润和非GAAP净利润进一步提升，分别达到4.64亿美元和8.20亿美元;经营活动产生的净现金持续为正且自由现金流达到5.96亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","688235","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662576689","title":"百济神州：美国FDA批准百泽安®联合方案用于HER2阳性胃食管腺癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2662576689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662576689?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:15","pubTimestamp":1787706938,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4139","BK4588","ONC","BK4585","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661224094","title":"高盛：上调百济神州目标价至441.3美元，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2661224094","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661224094?lang=zh_cn&edition=full","pubTime":"2026-08-24 17:15","pubTimestamp":1787562956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","UDN","BK4585","UUP","ONC","BK4526","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660049264","title":"美股中概股盘前涨跌互现，哔哩哔哩跌3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660049264","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660049264?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:01","pubTimestamp":1787212907,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1228905037.USD","LU1051768304.USD","LU0456827905.SGD","ODDS","LU0918141705.HKD","BK4220","BK4551","BK4524","LU0348827113.USD","LU1993786604.SGD","BK4527","LU0228659784.USD","LU1267930227.SGD","BK4502","BK4504","BABU","LU0143863198.USD","LU0994945656.USD","LU1515016050.SGD","LU1880383440.USD","LU0106252389.USD","BK4558","LU1048596156.SGD","JD","BK4574","LU0310800965.SGD","BK4535","BK4099","IE00BF5LJ272.USD","LU0553294199.USD","LU0588546209.SGD","BK4543","BK4563","LU1688375341.USD","LU0545562505.USD","LU0918141887.USD","LU1242518931.SGD","LU1868837722.USD","LU2152927971.USD","LU0049853897.USD","HK0000306685.HKD","LU0072462343.USD","SG9999002463.SGD","BK4509","LU1046421795.USD","HK0000320264.USD","LU0072913022.USD","09988","LU1048588211.SGD","LU1152091168.USD","NERD","BK4085","ONC","BIDG","IE00BGV7N243.SGD","LU1242518857.USD","IE00B0JY6N72.USD","LU0329678170.USD","BK4575","BK4526","BK4566","LU0048575426.USD","LU0572944931.SGD","LU0051755006.USD","LU1868838027.USD","LU1008478684.HKD","ESPO","LU0426412945.USD","LU1769817096.USD","BK4531","LU0545039389.USD","BIDU","LU1188198961.HKD","LU0640798160.USD","BK4513","BK4579","09999","LU0456842615.SGD","BK4139","IE00B543WZ88.USD","BBYY","LU0370786039.SGD","09626","IE00BYV24P56.USD","BK4588","BK4587","LU0244354667.USD","LU1960683339.HKD","BK4532","BK4614","BK4122","KJD","LI","LU0261950470.USD","LU0348816934.USD","LU1961090484.USD","LU1152091754.HKD","BK4533","LU0359201885.HKD","LU0039217434.USD","BABX","LU0128525689.USD","LU0210526637.USD","09888","BILI","ONLN","LU0173614495.USD","LU1003077747.HKD","HK0000306701.USD","KBDU","LU1051769294.HKD","LU0593848301.USD","BK4552","IE00BMCWC346.EUR","BK4534","LU1043141396.HKD","BABA","IE00BGHQDM52.EUR","BK4514","LU0426417589.USD","BK4548","LU0651946864.USD","BABW","EVS.SI","LU0737861772.HKD","LU1046422090.SGD","LU0651947912.USD","LU0417516902.SGD","LU1023057109.AUD","BK4555","LU1794554557.SGD","LU0287142896.SGD","LU1807302812.USD","BK4612","LU1282648689.USD","TCOM","09961","BK4510","LU1823568750.SGD","LU0359201612.USD","BK4554","KBAB","LU0143863784.USD","LU1105468828.SGD","CLIX","IE00B3M56506.USD","DRGN","LU1228905540.USD","LU0328353924.USD","LU0359202008.SGD","IE00BVYPNQ40.USD","BK4577","LU0052756011.USD","LU0326950275.SGD","SG9999000475.SGD","BK4565","LU2148611432.USD","BK4607","LU1720050803.USD","LU0463099449.HKD","LU1235294995.USD","LU2226246903.HKD","HERO","IE00BVYPNP33.GBP","LU0661504455.SGD","IE00BFMHRM44.USD","ALBmain","09618","02015","BK4142","LU0251143458.SGD","LU1043141123.HKD","LU0348814723.USD","BK4581","LU0307460666.USD","LU0880133367.SGD","LU1880383366.USD","BK4501","BK4585","LU0329678337.USD","LU1121112475.USD","BK4538","LU1868837565.USD","NTES","LU0348825331.USD","LU0106959298.USD","LU0949170772.SGD","LU0561508036.HKD","LU0828237510.HKD","LU0501845795.SGD","IE00BPRC5H50.USD","HK0000165453.HKD","LU0594300419.USD","BK4503","BK4077","BK4505","LU0067412154.USD","LU0315179316.USD","LU0650527681.SGD","LU1769817179.HKD","688235","LU2399975544.HKD","HK0000320223.HKD","LU0048580855.USD","LU0979878070.USD","06160","LU0797268264.HKD","LU1115378108.SGD","BK4602","IE0008368742.USD","DRAG","IE00B5MMRT66.SGD","LU0047713382.USD","LU0821914370.USD","LU0738911758.USD","LU0327786744.USD","BABO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660466060","title":"百济神州：微涨1.34%，上半年营收222亿全球化放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2660466060","media":"E药资本界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660466060?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:39","pubTimestamp":1787045940,"startTime":"0","endTime":"0","summary":"截至今日收盘，百济神州报293.78元，上涨1.34%，成交额17.36亿，换手率5.147%，量比0.71，总市值约3051.75亿，TTM市盈率约143.263倍。基本面看，公司 上半年营业总收入 222.20 亿元同比增长 26.8%，其中产品收入 217.97 亿元，百悦泽全球销售 161.27 亿元、百泽安 29.84 亿元；归母净利润 32.71 亿元同比增长 627.1%，全球化放量带动盈利显著改善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-18/doc-ininttrk8609091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688235","06160","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125396547","title":"港股创新药概念股盘初活跃，金斯瑞生物科技、海西新药涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125396547","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125396547?lang=zh_cn&edition=full","pubTime":"2026-08-18 09:35","pubTimestamp":1787016939,"startTime":"0","endTime":"0","summary":"8月18日，港股创新药概念股盘初活跃，$金斯瑞生物科技(01548)$、$海西新药(02637)$涨超8%，$药明生物(02269)$、$云顶新耀(01952)$、$百济神州(06160)$、$药明合联(02268)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995583.HKD","LU0819121731.USD","02637","02268","BK4139","BK1521","LU0307460666.USD","LU0516422952.EUR","LU1720050803.USD","LU0348735423.USD","01952","LU1794554557.SGD","BK4585","SG9999002562.SGD","LU3063872942.SGD","LU0417516738.SGD","HK0000306685.HKD","LU2039709279.SGD","LU0516423174.USD","HK0000320264.USD","KURE","KCAI","02269","BK1191","LU0326950275.SGD","01548","LU0359201612.USD","LU0516422366.SGD","LU0572944931.SGD","LU1688375341.USD","LU1880383366.USD","LU0348825331.USD","VXUS","LU0039217434.USD","HK0000320223.HKD","LU0029874061.USD","LU0456827905.SGD","BK1574","BK4526","LU0128526141.USD","LU0052750758.USD","LU0140636845.USD","LU1242518931.SGD","BK1161","LU0181495838.USD","LU0456846285.SGD","LU2488822045.USD","BK1141","BK1610","LU0823426308.USD","LU0417516902.SGD","SG9999014674.SGD","LU0823426480.USD","LU0516422440.USD","IE00B0JY6N72.USD","LU1242518857.USD","BK1583","BK4588","LU0051755006.USD","BK1576","LU0359202008.SGD","BK1589","HK0000306701.USD","LU0856984785.SGD","LU0327786744.USD","SG9999002463.SGD","ONC","LU0043850808.USD","LU0516423091.SGD","LU0588546209.SGD","LU0979878070.USD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146940","title":"JPMorgan Chase & Co.增持百济神州(06160)411.972万股 每股作价约219.79港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146940","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659146940?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:18","pubTimestamp":1786706314,"startTime":"0","endTime":"0","summary":"8月11日，JPMorgan Chase & Co.增持百济神州(06160)411.972万股，每股作价219.7851港元，总金额约为9.05亿港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260814/20260814192003_51980.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260814/20260814192003_51980.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2106854487.HKD","BK4566","688235","LU2417539215.USD","IYF","LU1119994496.HKD","JPX","LU2357305700.SGD","XLF","BK4533","BK1583","LU0320765489.SGD","IYG","LU0689472784.USD","LU2552382132.HKD","FTXO","IE00BKVL7J92.USD","JPMLL","06160","EWH","IE00BLSP4452.SGD","LU1116320737.USD","LU2237443978.SGD","LU2237443465.HKD","LU2328871848.SGD","KURE","IE00BZ1G4Q59.USD","SG9999002232.USD","LU0323591593.USD","ONC","LU0211326839.USD","IXG","LU1894683348.USD","IE00BWXC8680.SGD","LU1629891620.HKD","UYG","LU0828237510.HKD","LU2462157665.USD","IE00BN8TJ469.HKD","VFH","TRUF","LU0211331839.USD","LU2552382215.SGD","TFNS","LU1496350502.SGD","JPMO","KBWB","PGF","JPO","FNCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659137609","title":"百济神州(06160)授出合共40764股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2659137609","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659137609?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:56","pubTimestamp":1786611374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年8月7日，董事会薪酬委员会根据2016期权及激励计划的条款授予362名承授人合共40,764股美国存托股份受限制股份单位。该等受限制股份单位相当于529,932股股份，约占本公告之日公司发行股份总数的0.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1770034418.SGD","LU0307460666.USD","BK4585","BK4526","BK4588","ONC","688235","LU0588546209.SGD","LU1251922891.USD","BK1500","KURE","LU0228659784.USD","BK0239","BK4139","BK1583","LU0828237510.HKD","BK1588","LU1969619763.USD","LU2328871848.SGD","06160","LU1719994722.HKD","BK1161","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992720","title":"吃药行情继续上演！甘李药业涨停，百济神州6连阳！华宝基金港股通医疗ETF、港股通创新药ETF逆市三连涨！","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992720","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658992720?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:25","pubTimestamp":1786447500,"startTime":"0","endTime":"0","summary":"8月11月，A股、港股大幅回调，医药资产受大市影响整体冲高回落，其中创新药产业链韧性凸显，批量成功收红。成份股再鼎医药领涨5.28%，权重龙头百济神州涨2.63%斩获6连阳，股价创年内新高！基金管理人评估的药ETF华宝的风险等级为R3-中风险，适宜平衡型及以上的投资者，港股通医疗ETF华宝、港股通创新药ETF华宝及其联接基金的风险等级为R4-中高风险，适宜积极型及以上的投资者。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-11/doc-inimyaaf7389173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KURE","BK1500","BK1161","06160","603087","LU1719994722.HKD","BK1588","LU1969619763.USD","LU1770034418.SGD","LU1251922891.USD","BK4585","BK0239","BK4139","LU0307460666.USD","LU1303224171.USD","BK1583","LU0228659784.USD","LU0828237510.HKD","BK4588","159316","159828","688235","FLHK","ONC","LU2328871848.SGD","LU0588546209.SGD","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993724","title":"百济神州宣布安泰适（注射用塔拉妥单抗）正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993724","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658993724?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:35","pubTimestamp":1786437325,"startTime":"0","endTime":"0","summary":"8月10日，由百济神州与安进公司共同负责中国（不含港澳台地区）商业化开发的安泰适（注射用塔拉妥单抗）正式投入临床使用。截至8月10日，全国17个城市29家医疗机构已开出首批处方。据悉，塔拉妥单抗为首个且目前唯一获批的靶向DLL3和CD3的T细胞衔接器（TCE），于8月7日启动供应，首批复盖全国80个城市、超200家医疗机构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837896326.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837896326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1500","KURE","BK4526","BK0239","LU0228659784.USD","BK1588","LU2328871848.SGD","BK4588","LU1251922891.USD","LU0307460666.USD","06160","LU1969619763.USD","LU0588546209.SGD","688235","LU0828237510.HKD","LU1770034418.SGD","BK1583","BK1161","ONC","BK4139","LU1719994722.HKD","LU1303224171.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965691","title":"港股异动 | 百济神州(06160)早盘涨超4% 与Revolution Medicines达成临床合作 将加快RAS赛道开发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965691","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658965691?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:42","pubTimestamp":1786412546,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州早盘涨超4%，截至发稿，涨2.72%，报219港元，成交额2.97亿港元。消息面上，8月10日，据百济神州官微消息，公司与Revolution Medicines,Inc.宣布达成一项多方面合作协议。根据协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与Revolution Medicines四款临床阶段RAS抑制剂中任意一款或多款药物的联合治疗方案;同时，双方还达成区域授权协议，百济神州获得Revolution Medicines上述候选药物在部分亚洲市场的独家开发及商业化权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0828237510.HKD","LU0109394709.USD","IE0009355771.USD","LU0307460666.USD","BK4139","IE00BJT1NW94.SGD","BK1500","IDNA","BK4526","PTH","ONC","KURE","LU2328871848.SGD","LU0889565916.HKD","IE0002141913.USD","KCAI","IE0009354923.USD","LU0228659784.USD","06160","IE00B4R5TH58.HKD","LU1303224171.USD","LU0588546209.SGD","CANC","IE00B2B36J28.USD","BK1588","IE00BFTCPJ56.SGD","BK1583","BBH","BK1161","LU1719994722.HKD","IE00BJJMRZ35.SGD","RVMD","688235","LU1251922891.USD","VXUS","LU1770034418.SGD","LU0320765992.SGD","BK0239","LU1969619763.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196566","title":"百济神州（06160）盘初涨3.94% 与安进联合开发及商业化的安泰适正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196566","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658196566?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:39","pubTimestamp":1786412383,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 盘初上涨3.94%，最新报221.60港元，成交额1.86亿港元。消息面上，百济神州8月11日早上宣布，由百济神州与安进公司共同负责在中国开发和商业化的安泰适正式投入临床使用。此外，8月10日，百济神州宣布与Revolution Medicines达成一项多方面合作协议。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987884","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4534","IBB","LU1770034418.SGD","BIB","IE00BJT1NW94.SGD","LU0828237510.HKD","LU1969619763.USD","BK4533","BK4599","LU0289739699.SGD","BK4585","IE00B4R5TH58.HKD","IE0009355771.USD","LU1023059063.AUD","LU1983299246.USD","BBH","LU0058720904.USD","LU2112291526.USD","LU0307460666.USD","LU2242646821.SGD","LU2468319806.SGD","PBE","BK1583","06160","LU0109394709.USD","LU0228659784.USD","ONC","BK4566","AMGN","688235","IE00B2B36J28.USD","PJP","SG9999001440.SGD","LU1057294990.SGD","IE0002141913.USD","BK1500","BK1588","LU0122379950.USD","LU1571399168.USD","LU0588546209.SGD","BK4588","IBBQ","LU2089984988.USD","LU2242652126.USD","TBXU","BK4139","BK4526","KURE","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965603","title":"中金：维持百济神州(06160)跑赢行业评级 目标价266港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965603","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658965603?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:16","pubTimestamp":1786410971,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持百济神州2026年和2027年盈利预测不变。该行维持跑赢行业评级，基于DCF模型，该行维持A/H/US股目标价340元/266港币/445美元。中金主要观点如下：公司近况8月10日，百济神州与Revolution Medicines宣布达成临床开发及区域商业化合作。该合作主要涉及两个部分：1)双方将评估并开展百济神州候选药物和Revolution的四款RAS抑制剂的联合治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688235","ONC","EWH","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950149","title":"百济神州与Revolution Medicines达成临床开发及区域商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950149","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950149?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:40","pubTimestamp":1786405224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBH","IDNA","LU0320765992.SGD","PTH","IE0009354923.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","ONC","IE00B2B36J28.USD","BK4526","RVMD","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4588","IE00B4R5TH58.HKD","BK4585","IE00BJT1NW94.SGD","CANC","BK4139","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950539?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765992.SGD","159938","BK0239","BK1574","BK1583","603087","LU1770034418.SGD","688235","09939","IDNA","BK1161","LU1719994722.HKD","LU0307460666.USD","IE0002141913.USD","BD","IE0009355771.USD","LU0109394709.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","BK4585","BK4526","LU1303224171.USD","PTH","BK4139","LU0588546209.SGD","LU2328871848.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0228659784.USD","BK1588","ONC","IE0009354923.USD","BBH","KURE","BK4588","IE00B2B36J28.USD","LU1969619763.USD","LU0828237510.HKD","06160","LU1251922891.USD","CANC","BK1515","IE00BJT1NW94.SGD","BK1500","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658958697","title":"瞄准“不可成药”靶点！百济神州与Revolution达成合作，布局RAS联合治疗赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2658958697","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658958697?lang=zh_cn&edition=full","pubTime":"2026-08-11 00:32","pubTimestamp":1786379520,"startTime":"0","endTime":"0","summary":"“创新药一哥”百济神州出手了。8月10日，百济神州宣布一则重磅消息：公司已经与专注于癌症药物研发的生物科技公司RevolutionMedicines达成协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与RevolutionMedicines四款临床阶段RAS(ON)抑制剂（RAS激活态抑制剂）中任意一款或多款药物的联合治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113836984610.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113836984610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","LU1303224171.USD","KURE","688235","LU0828237510.HKD","LU1770034418.SGD","BK1161","LU1969619763.USD","LU1719994722.HKD","BK1588","BK4526","BK1500","BK1583","BK4585","BK4588","LU0588546209.SGD","LU0228659784.USD","LU2328871848.SGD","ONC","BK4139","LU0307460666.USD","BK0239","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658601016","title":"交银国际：百济神州(06160)目标价上调至276港元 维持“买入“评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2658601016","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658601016?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:57","pubTimestamp":1786330638,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，将百济神州(06160)目标价由229.2港元上调至276港元，维持\"买入\"评级。百济神州第二季泽布替尼在适应症扩大、新患渗透加深、依从性和DoT提升等因素的推动下，再次取得超预期的销售成绩，同时替雷利珠海外开启放量通道，未来与HER2双抗联用将开辟1L HER2+胃癌治疗机会。该行上调公司2026-2028年净利预测，分别至10.26亿美元、15亿美元及20.08亿美元，以反映第二季超预期的业绩表现和最新指引。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","EWH","ONC","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658679842","title":"中金：百济神州“跑赢行业”维持评级 目标价升至266港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658679842","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658679842?lang=zh_cn&edition=full","pubTime":"2026-08-09 09:40","pubTimestamp":1786239600,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端中金发布研究报告称，综合考虑泽布替尼高增长以及费用控制，上调百济神州（06160）今年盈利预测34%至8.71亿美元，并调升2027年盈测38%至12亿美元。该行维持其“跑赢行业”评级，H股目标价升6.4%至266港元。该行表示，公司第二季业绩胜预期 ，收入同比增长30%，其中产品收入同比增长29%；GAAP预期同比增长151%至2.37亿美元，销售收入略胜于预期，超预期是由于泽布替尼高增长及费用控制良好。报告中提到，百济神州公司大幅上调主要航线，总收入航线预估约66亿至68亿美元；GAAP经营利润指引增至约10亿至11亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-09/doc-inimsnkv3665933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06160","ONC","EWH","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644339","title":"百济神州：胰腺癌中KRAS突变率约95%、MTAP缺失率约20%，重叠人群较容易识别","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644339","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657644339?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:41","pubTimestamp":1786110060,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯 ，百济神州在接受调研时表示，MTAP缺失和KRAS突变均属于人类肿瘤中的高频分子事件，理论上存在较多联合机会。胰腺癌中KRAS突变率约95%、MTAP缺失率约20%，重叠人群较容易识别。肺腺癌中KRAS突变在欧美人群约30%、中国人群约10%，再叠加MTAP缺失后目标人群会明显缩小。公司会在肺癌开展探索，其他瘤种则主要根据两类突变的重叠率和早期临床信号确定优先级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-07/doc-inimpfya9837948.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-07/doc-inimpfya9837948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688235","BK1161","LU1969619763.USD","BK4526","LU2328871848.SGD","BK4139","BK1500","LU0588546209.SGD","LU1251922891.USD","KURE","LU1719994722.HKD","LU1770034418.SGD","BK1583","BK1588","BK4585","LU0307460666.USD","LU1303224171.USD","ONC","BK0239","BK4588","06160"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.1531},{"period":"3month","weight":0.2933},{"period":"6month","weight":0.1855},{"period":"1year","weight":0.2165},{"period":"ytd","weight":0.237}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0152},{"period":"6month","weight":0.1168},{"period":"1year","weight":0.1874},{"period":"ytd","weight":0.1234}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"　　百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.083709},{"month":2,"riseRate":0.6,"avgChangeRate":0.027535},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.02929},{"month":4,"riseRate":0.363636,"avgChangeRate":0.018832},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.019621},{"month":6,"riseRate":0.454545,"avgChangeRate":0.010403},{"month":7,"riseRate":0.818182,"avgChangeRate":0.143728},{"month":8,"riseRate":0.636364,"avgChangeRate":0.048292},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,ONC,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}